Meridian Bioscience Inc. (VIVO): Price and Financial Metrics
GET POWR RATINGS... FREE!
VIVO POWR Grades
- VIVO scores best on the Value dimension, with a Value rank ahead of 96.78% of US stocks.
- The strongest trend for VIVO is in Momentum, which has been heading down over the past 31 weeks.
- VIVO's current lowest rank is in the Stability metric (where it is better than 22.42% of US stocks).
VIVO Stock Summary
- With a price/earnings ratio of 9.42, Meridian Bioscience Inc P/E ratio is greater than that of about only 16.8% of stocks in our set with positive earnings.
- In terms of twelve month growth in earnings before interest and taxes, Meridian Bioscience Inc is reporting a growth rate of 261.65%; that's higher than 92.67% of US stocks.
- Revenue growth over the past 12 months for Meridian Bioscience Inc comes in at 60.36%, a number that bests 90.84% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Meridian Bioscience Inc, a group of peers worth examining would be STRT, RFIL, ZUMZ, FKWL, and FSI.
- VIVO's SEC filings can be seen here. And to visit Meridian Bioscience Inc's official web site, go to www.meridianbioscience.com.
VIVO Valuation Summary
- VIVO's price/sales ratio is 2.8; this is 77.95% lower than that of the median Healthcare stock.
- Over the past 243 months, VIVO's price/sales ratio has gone up 1.5.
- Over the past 243 months, VIVO's price/sales ratio has gone up 1.5.
Below are key valuation metrics over time for VIVO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VIVO | 2018-10-04 | 3.0 | 3.6 | 25.8 | 18.3 |
| VIVO | 2016-02-08 | 4.2 | 4.9 | 23.0 | 13.9 |
| VIVO | 2014-04-17 | 4.8 | 5.8 | 24.5 | 15.5 |
| VIVO | 2014-02-28 | 4.6 | 5.5 | 23.4 | 14.8 |
| VIVO | 2012-03-27 | 4.9 | 5.8 | 29.0 | 18.6 |
| VIVO | 2006-02-08 | 6.1 | 7.0 | 42.2 | 24.9 |
VIVO Price Target
For more insight on analysts targets of VIVO, see our VIVO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $29.67 | Average Broker Recommendation | 1.25 (Strong Buy) |
VIVO Stock Price Chart Interactive Chart >
VIVO Price/Volume Stats
| Current price | $19.39 | 52-week high | $30.65 |
| Prev. close | $18.94 | 52-week low | $12.98 |
| Day low | $18.71 | Volume | 474,200 |
| Day high | $19.50 | Avg. volume | 681,628 |
| 50-day MA | $20.18 | Dividend yield | N/A |
| 200-day MA | $21.15 | Market Cap | 840.17M |
Meridian Bioscience Inc. (VIVO) Company Bio
Meridian Biosciences is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. The company was founded in 1976 and is based in Cincinnati, Ohio.
VIVO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $19.39 | $12.24 | -37% |
We started the process of determining a valid price forecast for Meridian Bioscience Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Meridian Bioscience Inc ranked in the 42th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Meridian Bioscience Inc ended up being:
- Interest coverage, a measure of earnings relative to interest payments, is 47.99; that's higher than 86.76% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than just 22.77% of the free cash flow producing stocks we're observing.
- VIVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 42.61% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -38% |
| 1% | -38% |
| 2% | -37% |
| 3% | -37% |
| 4% | -36% |
| 5% | -35% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as VIVO, try ICLR, ABT, FZMD, ICUI, and INFU.
Latest VIVO News From Around the Web
Below are the latest news stories about Meridian Bioscience Inc that investors may wish to consider to help them evaluate VIVO as an investment opportunity.
Meridian To Buy Urea Breath Test For H. Pylori From Otsuka America Pharmaceutical For $20MMeridian Bioscience Inc (NASDAQ: VIVO) has agreed to acquire the North American BreathTek business from Otsuka America Pharmaceutical Inc for $20 million in cash. The transaction will close in Meridian's fiscal fourth quarter, which ends in September. With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test to detect Helicobacter pylori. Meridian expects the acquisition to add more than $20 million of annual revenue, enhancin |
Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. for $20 million in cash. The transaction is expected to close in Meridian’s fiscal fourth quarter. With this acquisition, Meridian will assume the customer relationships in North America to su |
Investors Shouldn't Overlook The Favourable Returns On Capital At Meridian Bioscience (NASDAQ:VIVO)If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two... |
Meridian Bioscience to Hold Third Quarter Fiscal 2021 Financial Results Conference Call on August 6, 2021CINCINNATI, July 14, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter fiscal 2021 financial results Friday, August 6, 2021. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. To participate in the live call by |
XELA, SOHU, SEED among mid-day movers.Gainers: Red Cat Holdings (RCAT) +97%.Allied Healthcare Products (AHPI) +82%.Orbsat (OSAT) +45%.Exela Technolcorp (HBMD) +28%.Integrated Media Technology (IMTE) +22%.Sohu.com (SOHU) +21%.Losers: MediaCo (MDIA) -45%.SGOCO Group (SGOC) -46%.Mer Telemanagement Solutions (MTSL) -25%.Datasea (DTSS) -22%.Gatos Silver (GATO) -19%.Aridis Pharmaceuticals (ARDS) -17%.Origin Agritech (SEED) -17%.Takung Art (TKAT) -17%.Xtant Medical (XTNT) -16%.... |
VIVO Price Returns
| 1-mo | -7.22% |
| 3-mo | -11.70% |
| 6-mo | -15.33% |
| 1-year | -16.24% |
| 3-year | 25.12% |
| 5-year | 5.74% |
| YTD | 3.75% |
| 2020 | 91.30% |
| 2019 | -43.29% |
| 2018 | 28.02% |
| 2017 | -18.02% |
| 2016 | -9.91% |
Continue Researching VIVO
Want to see what other sources are saying about Meridian Bioscience Inc's financials and stock price? Try the links below:Meridian Bioscience Inc (VIVO) Stock Price | Nasdaq
Meridian Bioscience Inc (VIVO) Stock Quote, History and News - Yahoo Finance
Meridian Bioscience Inc (VIVO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...